IMUNON, Inc. announced on June 17, 2025, that an abstract highlighting Phase 1 proof-of-concept clinical trial results of IMNN-101, its DNA plasmid vaccine, was accepted for oral presentation. The presentation will take place at the 10th International Conference on Vaccines Research & Development, scheduled for November 5-7, 2025, in Boston, MA.
The data from the Phase 1 trial, previously announced in May 2025, demonstrated six-month durability of protection, with IMNN-101 inducing up to a 3-fold median increase in serum neutralizing antibody titers from baseline. The vaccine also showed a favorable safety profile with no serious adverse effects.
This recognition at a leading global vaccine conference underscores the significant potential of the PlaCCine technology platform, which offers advantages in durability, temperature stability, and manufacturing compared to current mRNA vaccines. IMUNON is actively seeking strategic partners to advance this innovative technology for protection against infectious agents.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.